SCHEMBL30765591

SCHEMBL30765591

CC(=O)NCc1cc2cnccc2[nH]1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NAMPT P43490 10/20 0.48
▸ CYP2C9 P11712 3/20 0.48
▸ MTNR1A P48039 3/20 0.48
▸ MTNR1B P49286 3/20 0.48
▸ F2 P00734 2/20 0.47
▸ DAO P14920 1/20 0.47
▸ CLK1 P49759 1/20 0.46
▸ CLK2 P49760 1/20 0.46
▸ CLK3 P49761 1/20 0.46
▸ CDK5 Q00535 1/20 0.46
▸ DYRK1A Q13627 1/20 0.46
▸ CDK5R1 Q15078 1/20 0.46
▸ CLK4 Q9HAZ1 1/20 0.46
▸ DYRK1B Q9Y463 1/20 0.46
▸ SMN1; SMN2 Q16637 1/20 0.45
▸ KDM4E B2RXH2 1/20 0.45
▸ ALDH1A1 P00352 1/20 0.45
▸ MAPT P10636 1/20 0.45
▸ HDAC3 O15379 2/20 0.44
▸ HDAC1 Q13547 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23452339 0.87 F2 (0.48) NAMPTCYP2C9F2DAOSMN1; SMN2
SCHEMBL23491228 0.83 NAMPT (0.46) NAMPTCYP2C9F2DAOSMN1; SMN2
SCHEMBL23493049 0.83 CYP2A6 (0.46) NAMPTCYP2C9F2DAOMAPT
SCHEMBL23461311 0.83 F2 (0.52) NAMPTCYP2C9F2DAOSMN1; SMN2
SCHEMBL23461309 0.83 F2 (0.52) NAMPTCYP2C9F2DAOSMN1; SMN2
SCHEMBL30632885 0.82 SMN1; SMN2 (0.48) NAMPTCYP2C9F2SMN1; SMN2
SCHEMBL23478663 0.82 SMN1; SMN2 (0.48) NAMPTCYP2C9F2SMN1; SMN2
SCHEMBL23452548 0.80 F2 (0.61) NAMPTCYP2C9F2DAOSMN1; SMN2
SCHEMBL23452545 0.80 F2 (0.61) NAMPTCYP2C9F2DAOSMN1; SMN2
SCHEMBL13415981 0.79 MTNR1A (0.73) MTNR1AMTNR1BSMN1; SMN2KDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4568666-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS Alexion Pharmaceuticals, Inc. (US) 2025-06-18 — — EP disclosed
CN-119768164-A Pharmaceutical compounds for treating complement-mediated disorders 阿雷克森制药公司 2025-04-04 — — CN disclosed
WO-2024035686-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS ALEXION PHARMACEUTICALS, INC. (US) 2024-02-15 — — WO disclosed
Send feedback